Vyalev a continuous subcutaneousinfusion for Parkinson’s disease is now launched in Japan – AbbVie
AbbVie has launched Vyalev (foslevodopa + foscarbidopa), a continuous subcutaneous infusion for Parkinson’s disease, in Japan on July 26. This is the first Parkinson’s drug in the country that can be continuously infused for 24 hours without requiring surgery. In Japan, Vyalev was approved in December 2022 for the improvement of wearing-off symptoms in Parkinson’s inadequately controlled with existing pharmacotherapies […]
Recent Comments